The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | ctDNA as a biomarker for post-resection colorectal cancer recurrence
Julien Taieb, MD, PhD, Paris Descartes University, Paris, France, discusses circulating tumor DNA (ctDNA) as an indicator for disease recurrence following resection of non-metastatic colorectal cancer. Currently, all patients are treated further following this resection to prevent recurrence, inevitably exposing healthy patients to drug toxicities. Identifying patients who are unlikely to experience recurrence (those with low/no ctDNA) could combat this, though it is still necessary to generate more knowledge surrounding which tests to use and when. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
